Sign inJoin waitlistJoin the waitlist

CF

Charles Foucar

Physician · University of New Mexico School of Medicine

Credentials: · · · · · · ·

History

University of New Mexico School of Medicine
2022–Present

Hematology and Medical Oncology
University of Michigan
2017–2020
Internal Medicine
McGaw Medical Center of Northwestern University
2014–2017
Feinberg School of Medicine
2010–2014

Research

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022
Journal of the National Comprehensive Cancer Network · 2022 · 113 citations
Left Atrial and Left Atrial Appendage 4D Blood Flow Dynamics in Atrial Fibrillation
Circulation Cardiovascular Imaging · 2016 · 94 citations
Tetraploidization increases sensitivity to Aurora B kinase inhibition
Cell Cycle · 2012 · 20 citations

RS
Rory Shallis
7 papers
Anand Patel
6 papers
Dale Bixby
6 papers
Talha Badar
6 papers
Mark Wick
5 papers
Vamsi Kota
5 papers
Alexander Coltoff
4 papers · 2 as a fellow
Ehab Atallah
4 papers
OJ
Omer Jamy
4 papers
Yasmin Abaza
4 papers
AG
Aaron Goldberg
3 papers
AD
Adam DuVall
3 papers

Clinical trials

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027